NFE2L2 and myeloid sarcoma: Dimethyl fumarate, an activator of the Nrf2 pathway, is a Food and Drug Administration- and European Medicines Agency-approved first-line oral therapy for patients with relapsing forms of multiple sclerosis (MS) [12].